Open Accessibility Menu

Coronavirus (COVID-19) Update - We are open with your safety in mind. Click here to learn more.

For information about COVID-19, the vaccine, or to view additional resources, please click here.

Lou Gehrig’s Disease (ALS)

John J. Kelly ALS Clinic in Washington DC

Lou Gehrig’s disease involves the degeneration of nerve cells in the brain and spinal cord. It affects muscles involved in everything from limb movement to breathing.

To diagnose and treat affected patients, and to support their families and other caregivers, the John J. Kelly ALS Clinic at The GW Medical Faculty Associates deploys a collaborative, multidisciplinary team. It includes a board-certified neuromuscular neurologist, a board-certified pulmonologist, a neuromuscular nurse practitioner, and a clinical research coordinator as well as a speech-language pathologist, physical and occupational therapists, a dietitian, and a social worker who is an ALS specialist.

Members of the team are present at each visit; their different points of view are considered in each decision. Patients’ and caregivers’ opinions are respected as well, because our goals are the same: to help patients achieve the best possible quality of life.

Certified ALS Centers must meet strict criteria established by the National ALS Association and be involved in ALS research. Our researchers are involved in studies that offer promise in the fight against the disease.

Conveniently Located

Clinical Trials

  • INSYTE: Management of Parkinson’s Disease Psychosis in Actual Practice (The INSYTE Study)
    The INSYTE Study will examine the current disease progression of Parkinson’s disease Psychosis (PDP), the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers.
  • Protocol H8H-MC-LAIJ, Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
    The objective of this Phase 3 study is to evaluate the efficacy of lasmiditan 200 mg and 100 mg on migraine headache pain freedom compared to placebo.